Lowering adalimumab dose for chronic eye inflammation
Treatments studied
Part of Eyes & vision clinical trials.
This study tests whether a lower dose of adalimumab (a biologic medication) can keep controlling chronic non-infectious uveitis (eye inflammation that is not caused by an infection) after it has been well-controlled for a long time. If you have stable eye inflammation and have been on the standard adalimumab dose (40 mg every 2 weeks) for at least 24 weeks, this trial may be suitable for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic non-infectious uveitis (long-term eye inflammation that is not due to an infection).
- Your eye inflammation has been fully controlled (no active disease) for at least 48 weeks (or 96 weeks if your uveitis is related to Behçet's disease).
- You have been on adalimumab (40 mg every 14 days) for at least 24 weeks and have not taken any oral steroids for at least 12 weeks.
- You have not changed any other immune-suppressing medications (like methotrexate or mycophenolate) in the last 12 weeks.
- You do not have any planned surgeries or other medical events that would require stopping adalimumab during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
This trial tests whether minocycline, an antibiotic that can also reduce inflammation, helps improve chronic autoimmune uveitis and protect vision. It may help by lowering ongoing immune irritation that damages the eye.
This study tests if checking the amount of adalimumab (a biologic drug) in your blood can help doctors safely lower your dose. If you have had rheumatoid arthritis under control for at least 6 months, this trial may help you take less medication while keeping symptoms away.
This trial tests whether adjusting the dose of adalimumab (a medicine used to treat inflammation) can keep eye inflammation under control in children with juvenile idiopathic arthritis or chronic anterior uveitis. If you or your child have had stable eye inflammation for at least 2 years while on adalimumab, this study may help find the best long-term dose.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.